DEINOVE Strengthens Its Business Development Activity with the Arrival of Sébastien Enault
July 24 2017 - 2:30AM
Business Wire
Sébastien Enault brings to the Company a proven track record
in the development of collaborations in the pharmaceutical field
and, in particular, in the anti-infective field.
Regulatory News:
DEINOVE (Paris:ALDEI) (Euronext Growth Paris: ALDEI), a biotech
company that discovers, develops, and produces high-value compounds
from rare bacteria, notably from the Deinococcus genus, announces
that Sébastien Enault joins the Executive Committee as Business
Development Director.
Sébastien Enault, Engineer in Pharmacology and Biotechnologies,
has structured and managed the Business Development of MedinCell, a
biopharmaceutical company specializing in long-acting drug
delivery. In ten years, he has contributed to the rapid growth of
the company, including the signing of partnerships and agreements
with major pharmaceutical companies. Recently, he was in charge of
the Business Development of Eligo Bioscience, a start-up hosted at
the Institut Pasteur in Paris, which develops a new generation of
ultra-targeted antibiotics.
Prior to his experience in the private sector, Sébastien
conducted research in pharmacology in the fields of infectious
diseases, oncology and neurology at the Faculty of Pharmacy in
Marseille, then at Cancer Research UK, and at Harvard Medical
School.
"We are pleased to welcome Sébastien to expand and promote our
portfolio of programs and products in the healthcare and cosmetics
markets, two major areas for the Company and in which his
experience will be very useful. He will also contribute to the
launch, planned next year, of our first cosmetic ingredients," says
Emmanuel Petiot, CEO of DEINOVE.
Sébastien Enault adds: "DEINOVE's approach is disruptive, both
from the standpoint of the biodiversity of its bank of strains and
its integrated technological platform. It offers significant
potential for the discovery of new molecules to build a portfolio
of products likely to attract pharmaceutical companies."
ABOUT DEINOVE
DEINOVE (Euronext Growth Paris: ALDEI) is a biotech company that
discovers, develops and produces compounds with industrial value
from rare microorganisms, for the healthcare, nutrition and
cosmetics markets.
These innovative production methods represent a sustainable and
competitive alternative.
For this, DEINOVE relies on two key assets:
- A unique strain bank with 6,000 rare
bacteria that have not yet been exploited, mainly of the
Deinococcus genus;
- A genetic, metabolic and fermentation
engineering platform that enables them to customize these natural
micro-factories, transforming them into new industry
standards.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170723005025/en/
DEINOVEEmmanuel Petiot, +33 (0)4 48 19 01
28CEOemmanuel.petiot@deinove.comorSébastien Enault, +33 (0)7
50 18 93 35Business
Developmentsebastien.enault@deinove.comorALIZE RP, Press
RelationsCaroline Carmagnol / Wendy Rigal, +33 (0)1 44
54 36 66deinove@alizerp.comorCoralie Martin, +33 (0)4 48 19
01 60Communication and IR Managercoralie.martin@deinove.com